|
|
|
HR0703 |
|
LRB093 19758 KEF 47577 r |
|
|
1 |
| HOUSE RESOLUTION
|
2 |
| WHEREAS, Hemophilia is a genetic condition affecting |
3 |
| approximately 700 persons in the State of Illinois; hemophilia |
4 |
| is characterized by the absence of one of the several clotting |
5 |
| factors necessary to control bleeding; the standard care for |
6 |
| the treatment of hemophilia is to replace the absent clotting |
7 |
| factors necessary to control bleeding; and
|
8 |
| WHEREAS, Without treatment, people with hemophilia face |
9 |
| frequent, spontaneous bleeding episodes in their joints |
10 |
| causing swelling in the joint, muscles, internal organs, and |
11 |
| brain; repeated bleeding episodes in joints result in a chronic |
12 |
| degenerative arthritic condition, which often leads to |
13 |
| frequent hospitalizations, permanent disability, and chronic |
14 |
| pain; bleeding episodes involving internal organs and the brain |
15 |
| can cause permanent damage, disability, and even death; and
|
16 |
| WHEREAS, Severe bleeding episodes result in lost time at |
17 |
| work and school, decreased quality of life, and inability to |
18 |
| perform basic living activities; and
|
19 |
| WHEREAS, With proper care and access to comprehensive |
20 |
| medical resources, persons with hemophilia can control |
21 |
| bleeding episodes and can lead productive lives; and
|
22 |
| WHEREAS, The Medical and Scientific Advisory Committee of |
23 |
| the National Hemophilia Foundation recommends recombinant |
24 |
| factor products as the treatment of choice for persons with |
25 |
| hemophilia VIII and IX; and |
26 |
| WHEREAS, Visits to Hemophilia Treatment Centers reduced |
27 |
| morbidity by 60 percent; and
|
28 |
| WHEREAS, The State of Illinois is committed to the proper |
29 |
| medical treatment of hemophilia; and
|